drugset
Drugs / Yimitasvir
last change Jun 2022 re-read 2 minutes ago

Yimitasvir

also known as DAG181 · DAG-181 DIPHOSPHATE · YIMITASVIR PHOSPHATE · Yimitasvir Phosphate Capsule

Small molecule

Developed for
chronic hepatitis C virus infection · cirrhosis of liver
Investigated by
Sunshine Lake Pharma Co., Ltd. · Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. · Peking University People's Hospital · R&G Pharma Studies Co.,Ltd.

Trials 8 · a red edge is where a trial was stopped

today NCT04565171 · Ph 1 NCT04552808 · Ph 1 NCT04155515 · Ph 3 NCT03487107 · Ph 3 NCT03593447 · Ph 2 NCT03610880 · Ph 1 NCT03458481 · Ph 2 NCT03462173 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT04565171 Apr 2021 → May 2022 impaired renal function disease Sunshine Lake Pharma Co., Ltd. Completed No outcome recorded
Phase 1 NCT04552808 Oct 2020 → Jun 2022 — Sunshine Lake Pharma Co., Ltd. Completed No outcome recorded
Phase 1 NCT03610880 Oct 2017 → Feb 2018 — Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. Completed No outcome recorded
Phase 1 NCT03462173 Dec 2014 → Jan 2015 chronic hepatitis C virus infection Sunshine Lake Pharma Co., Ltd. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT03593447 Mar 2018 → Apr 2019 chronic hepatitis C virus infection, cirrhosis of liver Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. Completed No outcome recorded
Phase 2 NCT03458481 Jul 2017 → May 2018 chronic hepatitis C virus infection Sunshine Lake Pharma Co., Ltd. Completed No outcome recorded
Phase 32 trials
Phase 3 NCT04155515 Jun 2019 → Aug 2020 chronic hepatitis C virus infection, cirrhosis of liver Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. Completed No outcome recorded
Phase 3 NCT03487107 Apr 2018 → Mar 2019 chronic hepatitis C virus infection Sunshine Lake Pharma Co., Ltd. Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Yimitasvir ClinicalTrials.gov intervention name — accepted as the source's own label NCT04552808 ↗
2

NCT03462173 ↗

NCT04565171 ↗
Known as DAG-181 DIPHOSPHATE ChEMBL registry synonym — accepted as the source's own label CHEMBL5095203 ↗
Known as DAG181 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04155515 ↗
4

NCT03458481 ↗

NCT03487107 ↗

NCT03593447 ↗

NCT03610880 ↗
Known as YIMITASVIR PHOSPHATE ChEMBL registry synonym — accepted as the source's own label CHEMBL5095203 ↗
Known as Yimitasvir Phosphate Capsule “Participants with End-stage renal disease will receive a single dose of Yimitasvir Phosphate Capsule.” NCT04565171 ↗
Action Inhibit “The mechanism of action of Yimitasvir is the specific inhibition of HCV non-structural protein NS5A” NCT04552808 ↗
Modality Small molecule — CHEMBL5095203 ↗
Route Oral “Capsule administered orally once daily” NCT03458481 ↗